Sources to keep nearby
The sources beside these KLOW peptide notes
Here’s the reading behind the pages. I’ve kept a short note beside each source so you can see what it tested and why its findings don’t automatically belong to KLOW.
Hair research, with the ingredient named
- Trachy and colleagues on peptide-copper complexes in mice, 1991
A short report about hair-follicle activity in mice. It’s background to the interest in copper peptides, rather than a trial showing a hair result for KLOW in people.
- Pyo and colleagues on human hair follicles in a lab, 2007
The peptide was AHK-Cu, rather than GHK-Cu. The follicles and cells were studied outside a person. “Human” here describes the tissue, not a clinical trial.
- Lee and colleagues on GHK with 5-aminolevulinic acid, 2016
A scalp preparation improved hair counts in men with pattern hair loss compared with placebo. It wasn’t GHK-Cu alone or the four-part KLOW blend.
- Philp and colleagues on thymosin beta-4 and hair growth, 2004
This rodent work used the full protein. TB-500 is a smaller fragment, so it can’t simply borrow the result.
Ingredient studies answering other questions
- Pickart and colleagues on GHK and skin research, 2015
A review of skin research. It offers background without establishing a hair benefit for the blend.
- Dalmasso and colleagues on KPV and bowel inflammation, 2008
Cell and mouse experiments. These findings don’t establish what KPV, or KLOW, does for human hair.
- Staresinic and colleagues on BPC-157 and rat Achilles tendons, 2003
The study found improved healing measures after tendon injury. It tested neither human hair nor the complete blend.
- Lee and Burgess on a BPC-157 infusion safety pilot, 2025
No adverse events were observed in two adults. That doesn’t establish long-term safety, uncommon risks or safety of combining ingredients.
- Hsieh and colleagues on BPC-157 and blood-vessel growth, 2017
Cell and animal findings. Cancer-related concerns drawn from this biology remain theoretical for KLOW.
FDA sources on identity, safety and status
- FDA’s TB-500 review, 2026
Distinguishes TB-500 from full-length thymosin beta-4 and reports finding no published study giving TB-500 to people. It also discusses missing safety information and limits in batch testing.
- FDA’s BPC-157 review, 2026
Discusses limited safety evidence and possible immune reactions. Those concerns aren’t measured rates of harm from KLOW.
- FDA’s KPV review, 2026
Describes missing basic safety tests and possible immune reactions. It doesn’t establish a blend safety record.
- FDA’s bulk-substance safety page
Current as of April 22, 2026. The relevant ingredients appear as “nominated but withdrawn,” with GHK-Cu limited to injectable routes. Taking back a nomination isn’t clearance.
- FDA’s questions and answers about compounding
Explains why a compounded medicine is not FDA-approved, even when it has a prescription.